Drugs / SPI-2012
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03135951 | May 2017 → Feb 2018 | breast cancer | Spectrum Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT01724866 | Mar 2013 → Aug 2014 | neutropenia | Spectrum Pharmaceuticals, Inc | Completed | Met primary |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT02953340 | May 2017 → Jun 2018 | breast cancer, neutropenia | Spectrum Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT02643420 | Jan 2016 → Jan 2018 | breast cancer, neutropenia | Spectrum Pharmaceuticals, Inc | Completed | Met primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-09-11 | Hanmi Pharmaceutical Company Limited | SPI-2012, a novel long-acting GCSF utilizing a proprietary platform technology of Hanmi, advances to Phase 3 hanmipharm.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPI-2012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02643420 ↗ |
| Modality | Protein / enzyme biologic | “a novel, long-acting myeloid growth factor” PMID 29573207 ↗ Mar 2018 |
| Route | Subcutaneous | “SPI-2012 45 microgram/kilogram (µg/kg), subcutaneously (SC) once per cycle” NCT01724866 ↗ |